Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Mellissa Hicks"'
Supplemental Figures S1-5. Figure S1. Nutlin inhibits γH2AX foci formation and prolongs resolution. Figure S2. Inhibition of pS/TQ foci formation and resolution by Nutlin. Figure S3. Nutlin inhibits γH2AX foci formation and resolution in ovarian ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a01bb127f64ec5acbb32e2f55e59837
https://doi.org/10.1158/1541-7786.22514469
https://doi.org/10.1158/1541-7786.22514469
Autor:
Tyler L. Bloomer, Gregory E. Plautz, Yaomin Xu, Laura Deeanne Craig-Owens, Andrew H. Lichtman, Joshua M. Gorham, Mark A. Pilkinton, Daniel Reshef, Margaret L. Compton, Mellissa Hicks, Dan M. Roden, Christine E. Seidman, Nina Kola, Matthew R Alexander, Raquel P. Deering, Robert A. Anders, Douglas B. Johnson, Jason R Becker, Javid Moslehi, Igor J. Koralnik, Jeffrey A. Sosman, Benjamin A. Olenchock, Igor Puzanov, Spyridon Chalkias, Robert D. Hoffman, Luis A. Diaz, Jonathan S. Deutsch, David Slosky, Elizabeth J. Phillips, Janis M. Taube, Justin M. Balko, Jonathan G. Seidman
Publikováno v:
New England Journal of Medicine. 375:1749-1755
Immune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy. We report the cases of two patients with melanoma in
Autor:
Monica V. Estrada, Melinda E. Sanders, David B. Solit, Helen Won, Mellissa Hicks, IA Mayer, Justin M. Balko, Lew Cantley, Nancy Bouvier, M.F. Berger, CL Arteaga
Publikováno v:
Cancer Research. 76:P3-07
Background: Activation of the phosphoinositide-3-kinase (PI3K) pathway has been associated with resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer. Recently, we reported a Stand Up 2 Cancer (SU2C) Phase Ib trial of bupa
Autor:
Monica V. Estrada, Melinda E. Sanders, Roberto Salgado, Mellissa Hicks, CL Arteaga, Justin M. Balko, Rebecca S. Cook
Publikováno v:
Cancer Research. 77:P2-04
Background: Neoadjuvant chemotherapy (NAC) is frequently used in triple negative breast cancers (TNBC), and patients who achieve pathological complete response (pCR) following NAC have improved outcomes over those with residual disease (non-pCR). Unf
Autor:
Robert Wesolowski, Charles L. Shapiro, Bhuvaneswari Ramaswamy, Susan Friedman, Jenny Querry, Rachel M. Layman, Mellissa Hicks, Mahmoud Abdel-Rasoul, Ewa Mrozek, Maryam B. Lustberg, Erin Macrae
Publikováno v:
The Oncologist. 20:337-343
Background. Randomized clinical trials (RCT) that evaluated the addition of lapatinib to trastuzumab plus neoadjuvant chemotherapy (NAC) in patients with HER2-positive, operable breast cancer revealed a questionable improvement in pathologic complete
Publikováno v:
Molecular and Cellular Biochemistry. 403:115-124
The mitogen-activated protein kinase (MAPK) pathway is aberrantly activated in many human cancers, including breast cancer. Activation of MAPK signaling is associated with the increased expression of a wide range of genes that promote cell survival,
Publikováno v:
Biochemical and Biophysical Research Communications. 450:19-24
Chemotherapy resistance is a major obstacle to achieving durable progression-free-survival in breast cancer patients. Identifying resistance mechanisms is crucial to the development of effective breast cancer therapies. Immediate early genes (IEGs) f
Publikováno v:
Molecular cancer research : MCR. 13(8)
The Mdm2 oncogene is a negative regulator of the p53 tumor suppressor and recently identified inhibitor of DNA break repair. Nutlin-3 is a small-molecule inhibitor of Mdm2–p53 interaction that can induce apoptosis in cancer cells through activation
Autor:
Katie Hutchinson, Melinda E. Sanders, Violeta Sanchez, Justin M. Balko, Mellissa Hicks, Angel Guerrero, Luis J. Schwarz, Kyungmin Lee, Jennifer M. Giltnane, Taekyu Lee, Carlos L. Arteaga, Edward T. Olejniczak, Stephen W. Fesik
Publikováno v:
Cancer Research. 77:3890-3890
Cytotoxic chemotherapy is the standard of care for patients with triple negative breast cancer (TNBC). Most patients with advanced TNBC progress after chemotherapy and die from metastatic disease. MCL1 is an anti-apoptotic Bcl-2 family member known t
Autor:
Melinda E. Sanders, Jennifer M. Giltnane, CL Arteaga, Monica V. Estrada, Mellissa Hicks, Philip Owens, Justin M. Balko, Rebecca S. Cook, Preston D. Moore
Publikováno v:
Cancer Research. 76:PD6-01
Background: We have previously identified the MAPK phosphatase dual specificity phosphatase 4 (Dusp4) as frequently down-regulated in triple-negative and basal-like breast cancer (TNBC and BLBC, respectively). DUSP4 is deregulated in BLBCs by heteroz